Recently, starting from the observation that cancer cells that have defective checkpoints, often because of p53 pathway mutations, can still stop the cell cycle and avoid DNA damage-induced cell death by relying on the other checkpoint branches [33], a novel anticancer therapeutic strategy has begun to develop. This evidence concerns the gene TP53 and cancer.